Long-term recovery and vaccination cost-effectiveness for tick-borne encephalitis in the Czech Republic
Official title: Clinical and Public-Health Impact of Tick-Borne Encephalitis: A Prospective Multicenter Observational Study With 12-Month Follow-up and Cost-Effectiveness Analysis
Run by Charles University, Czech Republic · NCT07274046 · Data updated 2026-11-12
This project follows children and adults hospitalized with tick-borne encephalitis in the Czech Republic to see how they recover, which symptoms persist, and to estimate the health and economic benefits of vaccination.
Quick facts
| Study type | Observational |
|---|---|
| Sex | All |
| Enrollment | 209 (estimated) |
| Sponsor | Charles University, Czech Republic Academic / other |
| Locations | 4 sites (Ostrava, Moravian-Silesian Region and 3 other locations) |
| Status | Recruiting |
| Started | April 1, 2023 |
| Main results expected | December 2025 |
| Study ends | December 2026 |
| Registry record updated | December 10, 2025 |
| Trial ID | NCT07274046 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal participants are children or adults hospitalized with laboratory-confirmed TBE who can provide informed consent (or have a legal guardian provide consent) and can attend or be contacted for scheduled follow-up assessments.
✕Probably not a fit
Patients without laboratory confirmation of TBE, those with an alternative diagnosis explaining their neurological symptoms, or those unable to complete follow-up are unlikely to gain direct benefit from the study's clinical or policy findings.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a prospective multicenter observational study enrolling children and adults hospitalized with laboratory-confirmed TBE across major Czech infectious disease centers. Participants receive standardized clinical, functional, and quality-of-life assessments at discharge and at 2–4 weeks, 3 months, 6 months, and 12 months to map recovery trajectories and identify persistent symptoms characterized as post-encephalitic syndrome. Acute disease severity is categorized using predefined clinical criteria including paresis, ICU admission, prolonged hospitalization, or death. The dataset is combined with health-economic analyses to model the potential population-level impact and cost-effectiveness of broader TBE vaccination in this high-incidence setting.
Why it matters
Potential benefit: If successful, the findings could improve post-TBE follow-up and rehabilitation and inform vaccination policies that reduce future cases and long-term disability.
How similar studies have gone: Previous cohort studies have documented persistent post-encephalitic symptoms and economic models have supported TBE vaccination in some settings, but large prospective multicenter data linking clinical sequelae and cost-effectiveness in a high-incidence country remain relatively limited.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Hospitalization due to suspected central nervous system (CNS) infection. * Laboratory-confirmed TBE, defined as: the presence of CNS symptoms and cerebrospinal fluid pleocytosis (\>5 × 10⁶/L) and TBEV IgM and IgG seropositivity in serum, or detection of TBEV IgM in CSF in previously vaccinated individuals. * All age groups (children and adults). * Ability to participate in scheduled follow-up (in person or via telephone). * Informed consent provided by the patient or legal guardian (for minors). Exclusion Criteria: * Alternative diagnosis explaining the CNS symptoms * Missing essential clinical or laboratory data required to confirm TBE or assess outcomes. * Refusal or inability to provide informed consent. * Inability to complete follow-up assessments, including situations where reliable contact cannot be maintained. * Coexisting severe neurological disorder unrelated to TBE that prevents meaningful evaluation of sequelae (e.g., advanced neurodegenerative disease, severe preexisting motor disability).
Where it's running
-
Ostrava University Hospital
Ostrava, Moravian-Silesian Region, Czechia Recruiting -
Pardubická nemocnice
Pardubice, Pardubice Region, Czechia Recruiting -
Bulovka University Hospital
Prague, Prague, Czechia Recruiting -
České Budějovice Hospital
České Budějovice, South Bohemian Region, Czechia Recruiting
Study contacts
- Study coordinator: Martin Slížek, MD
- Email: martin.slizek89@gmail.com
- Phone: 00420602269494
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Tick-borne infections in Finland: a broad, multicenter look at Lyme, TBE and other infections
This study tests how common and how these infections show up in people with suspected tick-borne disease in Finland.
-
Community spread of multiple infectious diseases in Cambodia from a One Health perspective
This project will test how common and connected dengue, chikungunya, Zika, Japanese encephalitis, and West Nile infections are among people, animals, and the environment across Cambodia.
-
Dexamethasone for tick-borne encephalitis
This trial will see if dexamethasone helps adults with confirmed tick-borne encephalitis who have meningitis, encephalitis, or meningomyelitis.
-
Investigating tick-borne encephalitis and borrelial antibodies in patients
This study is testing if giving antibiotics helps patients in Slovenia with tick-borne encephalitis symptoms and positive borrelial antibodies, even if they don't have Lyme disease.
-
General practitioners' knowledge of tick-borne encephalitis in France
This project will test how well general practitioners in France recognize and manage tick-borne encephalitis after a tick bite.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.